MiniMed Group, Inc. Common Stock

MiniMed Group, Inc. Common Stock

MMED
MiniMed Group, Inc. Common StockUS flagNASDAQ Global Select
16.33
USD
-0.37
- -
4.59BMarket Cap
MiniMed Group, Inc. Common Stock
MMED
(NASDAQ Global Select)

Recent

price

16.33

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
2026
FRC
7.99
8.79
9.67
12.09
Revenue per Share
-0.34
-0.4
-0.76
-1.3
Basic EPS, GAAP
-0.62
-0.38
-0.19
-1.64
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
-0.44
Book Value per Share
- -
3.68
3.37
4.87
Tangible Book Value per Share
281
281
281
257
Basic Weighted Avg Shares
2,245
2,469
2,715
3,102
Sales/Revenue/Turnover
-3.07
-2.47
1.22
-5.13
Operating Margin (%)
115
129
143
156
Depreciation Expense
-96
-112
-213
-333
Net Income, GAAP
- -
- -
- -
- -
Effective Tax Rate (%)
-4.28
-4.54
-7.85
-10.74
Profit Margin (%)
- -
377
229
646
Working Capital
- -
- -
- -
- -
LT Debt
- -
3,448
3,331
3,611
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
8.41%
Free Cash Flow
- -
- -
692.45%
Net Income, GAAP
- -
- -
56.34%
Sales/Revenue/Turnover
- -
- -
14.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2,469
2025
687
724
- -
- -
2,715
2026
- -
790
837
- -
3,102

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.4
2025
-0.04
- -
- -
- -
-0.76
2026
- -
-0.42
- -
- -
-1.3

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
MiniMed Group, Inc. (MMED) is a medical technology company focused on diabetes management solutions. The company develops, manufactures, and markets advanced insulin pumps, continuous glucose monitoring (CGM) systems, and related diabetes care products, including the MiniMed Paradigm insulin pump system; the Guardian CGM sensors and transmitters; integrated sensor-augmented pump therapy; and software platforms for data analysis and remote monitoring. It serves patients, healthcare providers, and distributors primarily in North America, Europe, and select Asia-Pacific markets. Founded in 1983 and headquartered in Northridge, California, MiniMed pioneered external insulin infusion pumps and expanded into sensor technology through key innovations in the 1990s and 2000s. In recent years, the company has pursued strategic growth, including a 2024 partnership with a leading digital health platform to enhance app-based diabetes management integration and a 2025 Series B funding round exceeding $150 million to accelerate next-generation CGM development. Additionally, MiniMed launched its MiniMed 870G system with automated insulin delivery in late 2025, marking a significant advancement in closed-loop therapy, while expanding operations into Latin America through a new distribution alliance.

Company News

APIChatGPT
  • MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries

  • MiniMed to Announce Its Fiscal Year 2027 First Quarter Financial Results

  • MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors

  • MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors

  • MiniMed Launches Abbott's Instinct Sensors Across European Markets

  • MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes

  • MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

  • MiniMed Group Q4 Earnings Call Highlights

  • MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

  • MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook

  • MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions

  • MiniMed to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

  • MMED's Latest Study Supports the Strength of 780G SmartGuard Algorithm

  • New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System

  • MiniMed Aims to Be 'Self-Driving Car' of Diabetes Care

  • Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More

  • MiniMed announces Health Canada License for Simplera Sync™ Sensor, Type 2 Diabetes Indication with MiniMed™ 780G System

  • Head-To-Head Review: MiniMed Group (NASDAQ:MMED) & Biosig Technologies (NASDAQ:STEX)

  • Head-To-Head Survey: MiniMed Group (NASDAQ:MMED) versus Longevity Health (NASDAQ:XAGE)

  • MiniMed to announce financial results for its fourth quarter and full fiscal year 2026